We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+39.36%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$417M
AUM Growth
+$55.3M
Cap. Flow
+$13M
Cap. Flow %
3.12%
Top 10 Hldgs %
91.13%
Holding
24
New
3
Increased
5
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
SVRA icon
Savara
SVRA
+$14.4M
2
ANAB icon
AnaptysBio
ANAB
+$8.47M
3
OBSV
ObsEva SA Ordinary Shares
OBSV
+$5.97M
4
SPRO icon
Spero Therapeutics
SPRO
+$5.96M
5
GYRE icon
Gyre Therapeutics
GYRE
+$1.6M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$11.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$6.76M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.31M
4
PDSB icon
PDS Biotechnology
PDSB
+$3.06M
5
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$2.77M

Sector Composition

Rank Sector Weight
1 Healthcare 92.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$115M 27.47%
1,035,657
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$46.4M 11.11%
1,718,605
+54,305
+3% +$1.5M
ASND icon
3
Ascendis Pharma A/S
ASND
$17.1B
$44.6M 10.69%
1,113,014
-186,038
-14% -$6.76M
ARGX icon
4
argenx
ARGX
$53.8B
$41M 9.83%
649,665
+2,650
+0.4% +$86.8K
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
$34.2M 8.2%
854,057
-53,000
-6% -$2.04M
ANAB icon
6
AnaptysBio
ANAB
$1.72B
$28.5M 6.82%
282,550
+115,000
+69% +$8.47M
OBSV
7
DELISTED
ObsEva SA Ordinary Shares
OBSV
$19.4M 4.65%
1,988,843
+587,500
+42% +$5.97M
SVRA icon
8
Savara
SVRA
$1.13B
$18.7M 4.48%
+1,259,500
New +$14.4M
BCRX icon
9
BioCryst Pharmaceuticals
BCRX
$2.36B
$12.2M 2.92%
2,482,119
-683,338
-22% -$3.31M
BLPH
10
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$9.67M 2.32%
276,625
– –
PDSB icon
11
PDS Biotechnology
PDSB
$41.1M
$9.14M 2.19%
48,755
-15,208
-24% -$3.06M
SPRO icon
12
Spero Therapeutics
SPRO
$91.5M
$5.71M 1.37%
+485,615
New +$5.96M
RARX
13
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$4.63M 1.11%
544,612
-225,159
-29% -$2.77M
GYRE icon
14
Gyre Therapeutics
GYRE
$675M
$3.21M 0.77%
+31,423
New +$1.6M
AKTX
15
Akari Therapeutics
AKTX
$19.3M
$1.85M 0.44%
533
– –
ORKA
16
Oruka Therapeutics
ORKA
$5.59B
$1.46M 0.35%
4,995
– –
LPCN icon
17
Lipocine
LPCN
$18.4M
$1.33M 0.32%
22,760
– –
ADVM
18
DELISTED
Adverum Biotechnologies
ADVM
– –
-28,000
Closed -$1.02M
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
– –
-221,651
Closed -$1.49M
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$12.8B
– –
-30,000
Closed -$1.35M
SIOX
21
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-9,520
Closed -$524K
MYOK
22
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-265,000
Closed -$11.4M
OCRX
23
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-477,269
Closed -$544K

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q4 2017 Portfolio in Review

As of Q4 2017, VHCP Management II held 24 positions worth $417M, up 15% from $362M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

VHCP Management II deployed $13M of net new capital in Q4 2017, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Savara: 1,259,500 shares worth $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $6.76M trimmed.

  • VHCP Management II's largest Q4 2017 buy was Savara: 1,259,500 shares worth $18.7M.
  • VHCP Management II added most to AnaptysBio in Q4 2017, an estimated $8.47M increase.
  • VHCP Management II's biggest Q4 2017 reduction was Ascendis Pharma A/S, cutting an estimated $6.76M.
  • VHCP Management II fully exited MyoKardia, Inc. Common Stock in Q4 2017, selling an estimated $11.4M.
  • VHCP Management II's ten largest holdings make up 91% of its $417M portfolio in Q4 2017.
  • VHCP Management II opened 3 new positions and closed 6 in Q4 2017.
  • VHCP Management II's portfolio value rose 15% quarter-over-quarter to $417M.

Based on VHCP Management II's 13F filing for Q4 2017, filed 13 Feb 2018.